Abstract: The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

Abstract: Identification of gene variants, and in particular identification of differences between sequence variants that occur in a population of nucleic acid molecules, especially identification or discovery of polyA site usage, or determination of polyA site usage in a nucleic acid sample, and gene variants arising from alternative polyA sites.

Abstract: Methods of manipulation of nucleic acid, in particular amplification by means of the polymerase chain reaction (PCR), including use of oligonucleotides and combinations and kits comprising such oligonucleotides, also methods comprising use of nested PCR, allowing for improved results in methods wherein large numbers of nucleic acid fragments are manipulated by means of PCR and electrophoresis. Oligonucleotides are provided for use a size standards in electrophoresis, and internal controls allowing for calculation of relative amounts of material present. Improved results can be achieved in methods of profiling mRNA transcribed in a system under investigation.

Abstract: A method for identifying mRNA molecules present in a sample, and also for quantifying the expression levels of the mRNA molecules. A profile of gene identities and/or expression levels is produced by generating two independent patterns characteristic of the population of mRNA molecules expressed in the sample and analysing these patterns using a combinatorial algorithm. Gene expression by different cell types or of the same cell types under different conditions may be compared. In this way, genes may be identified which play a role in determining various cellular processes and states, including susceptibility to external factors, development, and disease.

Abstract: The present invention relates to selective neuropeptide Y (NPY) Y1 receptor antagonists. More closely, it relates to use of, and methods of using, selective NPY Y1 receptor antagonists for the treatment of inflammatory conditions. The invention also relates to use of a NPY Y1 receptor as a drug target in screening procedures to find anti-inflammatory compounds.